Therapeutic Effects of Lifei Decoction in a Murine Model of COPD Induced by LPS and Cigarette Smoke
International Journal of Chronic Obstructive Pulmonary Disease · 2024
DOI: 10.2147/copd.s449521 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2024. Verfasst von Liguo Lu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogenic Biology and Immunology, Xuzhou Medical University, Xuzhou, People's Repub…. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Disease Models, Animal, Lung, Drugs, Chinese Herbal. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: COPD
Abstract (Originalsprache)
Introduction
The Lifei Decoction (LD) is a commonly utilized Chinese medicine for the treatment of sepsis and bronchial inflammation. However, its therapeutic potential in chronic obstructive pulmonary disease (COPD) remains unknown. Therefore, the objective of this study was to investigate the therapeutic efficacy and underlying mechanism of LD in a mouse model of COPD induced by cigarette smoke (CS) combined with lipopolysaccharide (LPS).
Methods
Hematoxylin-eosin (H&E) staining was employed to observe the pathological alterations in lung tissue, while ELISA was utilized for the detection of levels of inflammatory factors in both lung tissue and bronchoalveolar lavage fluid (BALF). Additionally, Western blot analysis was conducted to assess the expression of p-NF-κB, GDF11, ZO-1, and Occludin-1 proteins. The changes in intestinal flora were evaluated using the viable bacteria count method.
Results
The administration of LD demonstrates significant efficacy in mitigating pulmonary tissue damage in a murine model, while concurrently inhibiting the activation of the inflammatory pathway NF-κB to attenuate the levels of pro-inflammatory factors. Moreover, LD exhibits the capacity to enhance the expression of intestinal functional proteins ZO-1 and Occludin-1, thereby rectifying dysbiosis within the gut microbiota.
Conclusion
The LD shows great promise as a potential treatment for COPD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogenic Biology and Immunology, Xuzhou Medical University, Xuzhou, People's Republic of China.
- Department of Respiratory and Critical Care Medicine, Shuyang Hospital, The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian, People's Republic of China.
- Department of Traditional Chinese Medicine, Shuyang Hospital, The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian, People's Republic of China.
- Taian Maternal and Child Health Hospital, Tai An, Shandong, People's Republic of China.
- Public Experimental Research Center, Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.
Zitieren
APA
Lu, L., Zhu, C., Xu, J., Hu, Y., Dai, J., Wang, S., & Wei, T. (2024). Therapeutic Effects of Lifei Decoction in a Murine Model of COPD Induced by LPS and Cigarette Smoke. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s449521
Vancouver
Lu L, Zhu C, Xu J, Hu Y, Dai J, Wang S, et al. Therapeutic Effects of Lifei Decoction in a Murine Model of COPD Induced by LPS and Cigarette Smoke. International Journal of Chronic Obstructive Pulmonary Disease. 2024. doi:10.2147/copd.s449521
BibTeX
@article{Lu2024,
author = {Lu, Liguo and Zhu, Chengdong and Xu, Jian and Hu, Yulan and Dai, Juxiang and Wang, Sheng and Wei, Tao},
title = {Therapeutic Effects of Lifei Decoction in a Murine Model of COPD Induced by LPS and Cigarette Smoke},
journal = {International Journal of Chronic Obstructive Pulmonary Disease},
year = {2024},
doi = {10.2147/copd.s449521}
}
EUVIMED